Randy Anderson, Ph.D.
Senior Vice President of Data Sciences
Randy Anderson, Ph.D., is a clinical development strategist for pharmaceuticals, biologics, and devices. He has 32 years of experience as a statistical scientist and clinical strategist, focusing primarily on products to treat diabetes, gastrointestinal disorders, or cancer. Dr. Anderson helped plan and oversee clinical development of dapoxetine (Priligy™), alogliptin (Nesina™), and albiglutide (Tanzeum™), from their first-in-human trials through marketing applications.
Most recently, Dr. Anderson served as co-founder and Vice President at Captains Ventures, Inc. providing clinical development planning to multiple biotechnology companies, for products to treat type 1 diabetes or cancer. From 2015 to 2018, he served Chiltern International as Senior Vice President of Scientific and Regulatory Affairs. In addition to direct product development work, from 1997-2010, Dr. Anderson built and led a staff of 250+ as Vice President of Biostatistics, Interactive Response Technologies, and Global Clinical Supplies at PPD, Inc. From 2010-2015, he served PPD, Inc. as Vice President of Global Product Development and therapeutic area leader for endocrine and metabolism diseases.
He received his B.A. in Zoology from the University of North Carolina at Chapel Hill. He earned M.S. (Experimental Psychology) and Ph.D. (Biostatistics) degrees from Virginia Commonwealth University, where he served as data analyst for the NIH NINDS Traumatic Coma Databank.
Dr. Anderson is a Director Emeritus with the Juvenile Diabetes Research Foundation and serves JDRF as a mentoring Research Champion for the Immunotherapies scientific staff.